Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action"
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Therapeutics".
Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 24059
A printed edition of this Special Issue is available here.
Special Issue Editor
Interests: cancer metabolism; NAD+ biology; sirtuins; cancer selectivity; novel targets; target deconvolution
Special Issue Information
The focus of this Special Issue is “Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism(s) of Action”. Whilst there have been significant improvements in treatments and outcomes for some cancers, for others there has been little change in survival rates over many years. Side effects resulting from the toxicity of agents towards normal tissues and the development of drug resistance can be a problem with both targeted and traditional anti-cancer agents. There is a pressing need for new anti-cancer agents with novel mechanism(s) of action and the identification of new putative cellular targets and therapeutic strategies that are both potent and more selective towards cancer cells. This Special Issue invites submissions in any area relating to these themes. Possible topics within this scope include (but are not limited to) the following:
- New promising compounds with in vitro and/or in vivo anti-cancer activity identified through a phenotypic approach, and studies on elucidating their mechanism(s) of action;
- New putative cellular targets that may offer cancer selectivity to targeting approaches (targeted therapies);
- Novel therapeutic approaches, such as combinatorial chemotherapy, that may confer synthetic lethality or improve selectivity;
- Drug re-purposing;
- Promising agents showing polypharmacology;
- Target deconvolution and target validation studies.
We invite authors to submit original research articles or review articles.
Dr. Simon J Allison
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- novel cellular anti-cancer targets
- phenotypic screening
- novel anti-cancer agents
- target deconvolution
- targeted therapies
- drug re-purposing
- combinatorial chemotherapy
- target validation